Abstracts tagged "Disease Activity"

Abstract Number: 1806 • 2017 ACR/ARHP Annual Meeting
Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Patricia P. Katz¹, Maria Dall'Era², Laura Trupin³, Stephanie Rush⁴, Charles G. Helmick⁵, Lindsey A. Criswell⁴ and Jinoos Yazdany³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: The BILD1,2 was developed and validated as a measure of SLE organ damage for use in epidemiologic studies in which administration of the SLICC…
Abstract Number: 2263 • 2017 ACR/ARHP Annual Meeting
Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus
Sarah L. Patterson¹, Gabriela Schmajuk², Kashif Jafri³, Katherine D. Wysham³ and Patricia P. Katz⁴, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of…
Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Philip J Mease¹, Jacqueline B. Palmer², Mark Lebwohl³, Chitra Karki⁴, George W. Reed⁵, Carol J. Etzel⁶, Jeffrey D. Greenberg⁷ and Philip S. Helliwell⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷New York University School of Medicine, New York, NY, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
Abstract Number: 2907 • 2017 ACR/ARHP Annual Meeting
Salivary Gland Enlargement in IgG4-Related Disease Is Associated with Multiorgan Involvement and Higher Basal Disease Activity
Eduardo Martín Nares¹, Jacobo Guerrero Castillo², Arturo Angeles Angeles² and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition which clinical spectrum encompasses single or multiple organ involvement. Enlargement of major and minor salivary glands is…
Abstract Number: 126 • 2017 ACR/ARHP Annual Meeting
Smoking Is Causally Associated with Disease Activity in Rheumatoid Arthritis
Milena Gianfrancesco¹, Laura Trupin², Stephen Shiboski³, Mark van der Laan⁴, Jonathan Graf⁵, John B. Imboden Jr.⁶, Jinoos Yazdany² and Gabriela Schmajuk⁷, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴University of California, Berkeley, Berkeley, CA, ⁵Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁶Medicine, University of California, San Francisco, San Francisco, CA, ⁷San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA
Background/Purpose: The association between smoking and risk of rheumatoid arthritis (RA) has been well documented; however, the relationship between smoking and RA disease activity is…
Abstract Number: 655 • 2017 ACR/ARHP Annual Meeting
Innate Lymphoid Cells – New Players in Psoriatic Arthritis
Alina Soare¹, Stefanie Weber², Lisa Maul³, Ana Maria Gheorghiu⁴, Ismail Housni⁵, Arnd Kleyer⁶, Markus Luber², Simon Rauber², David Simon⁶, Juergen Rech⁶, Georg Schett⁶, Jörg Distler¹ and Andreas Ramming⁷, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Innate lymphoid cells (ILCs) produce disease-related cytokines including IL-17 and IL-22 and are therefore of substantial interest in PsA. Spreading the disease from the…
Abstract Number: 1086 • 2017 ACR/ARHP Annual Meeting
Screening and Intervention of Depression in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rui Zhang¹, Priya Prakash², Amy Wasserman³, Kirk Sperber⁴ and Julia Ash⁵, ¹Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ²Rheumatology, NYMC /WMC, VALHALLA, NY, ³Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ⁴New York Medical College / Westchester Medical Center, Valhalla, NY, ⁵Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY
Background/Purpose: Depression is common and associated with worse outcomes among patients with RA and SLE. Our study assessed depression using Patient Help Questionnaire (PHQ-9) and…
Abstract Number: 1501 • 2017 ACR/ARHP Annual Meeting
Sexual Dysfunction and Vaginal Dryness Are Common in Female Patients with Early, Active Primary Sjogren’s Syndrome
Jolien F. van Nimwegen, Greetje S. van Zuiden, Frans G.M. Kroese, Suzanne Arends and Hendrika Bootsma, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose : The objective of this study was to evaluate the prevalence of sexual dysfunction and vaginal dryness in female patients with early, active primary…
Abstract Number: 1814 • 2017 ACR/ARHP Annual Meeting
Time Trends over a Decade Show Earlier Intensified Medication Strategies and Improved Outcomes in Canadians with Early Inflammatory Arthritis
Orit Schieir¹, Marie-France Valois², Susan J. Bartlett^3,4, Carol A Hitchon⁵, Janet E. Pope⁶, Gilles Boire⁷, Boulos Haraoui⁸, Diane Tin⁹, Carter Thorne¹⁰, Edward C. Keystone^11,12 and Vivian P. Bykerk^13,14, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²McGill University, Montreal, QC, Canada, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Institute de Rheumatologie, Montreal, QC, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Toronto, Newmarket, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹³Mount Sinai Hospital, Toronto, ON, Canada, ¹⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Treatment recommendations aim to improve outcomes in rheumatoid arthritis (RA) through early identification and a treat-to-target approach. We examined recent trends over the past…
Abstract Number: 2302 • 2017 ACR/ARHP Annual Meeting
The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis
Stephanie Shoop-Worrall¹, Suzanne M Verstappen², Janet E. McDonagh³, Wendy Thomson⁴ and Kimme L. Hyrich⁴, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal and Dermatology Research, Faculty of Medicine, Biology and Health, United Kingdom, University of Manchester, Manchester, United Kingdom, ³Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Information regarding longer-term outcomes in JIA largely pre-date the introduction of biologic therapies and have been cross-sectional. The aim of this analysis was to…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…
Abstract Number: 2908 • 2017 ACR/ARHP Annual Meeting
High Disease Activity Is a Predictor of Depression and Persistent Depression in Early Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Raman Joshi¹, Mohammad Movahedi², Bindee Kuriya³, Emmanouil Rampakakis⁴, Angela Cesta², Xiuying Li², Sandra Couto², John S. Sampalis⁵ and Claire Bombardier², ¹William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada
Background/Purpose: The prevalence of depression among individuals with rheumatoid arthritis (RA) may be as high as 40% but persistence of depression over time is relatively…
Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting
Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients
Jeffrey R. Curtis¹, Kerri Ford², Lang Chen³, Huifeng Yun³ and Fenglong Xie⁴, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Crescendo Bioscience Inc., South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…
Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting
A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Joan T. Merrill¹, Thierry Dervieux², Jill P. Buyon³, Rosalind Ramsey-Goldman⁴, Kenneth C. Kalunian⁵, Chaim Putterman⁶, John Conklin², Richard Furie⁷ and Michelle Petri⁸, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Exagen Diagnostics, Inc., Vista, CA, ³Medicine, New York University School of Medicine, New York, NY, ⁴FSM, Northwestern University, Chicago, IL, ⁵Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ⁷Northwell Health, Great Neck, NY, ⁸Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…
Abstract Number: 1152 • 2017 ACR/ARHP Annual Meeting
Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease
Seoung Wan Nam¹, SuMan Kang², Hyoungyoung Kim³, Ga-Young Ahn⁴, Min Jung Kim³ and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Diagnosis and accurate measurement of disease activity in adult-onset Still¡¯s disease (AOSD) are still challenging due to its heterogeneous clinical manifestations and the lack…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].